NCT05232864 - Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

August 23, 2023

Study Completion Date

August 23, 2023

Conditions

Lupus Nephritis

Interventions

DRUG

Secukinumab

300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)

Trial Locations (18)

2145

Novartis Investigative Site, Westmead

4217

Novartis Investigative Site, Lipa City

10400

Novartis Investigative Site, Bangkok

12808

Novartis Investigative Site, Prague

92101

Novartis Investigative Site, Piešťany

700000

Novartis Investigative Site, Ho Chi Minh City

60430 370

Novartis Investigative Site, Fortaleza

05403 000

Novartis Investigative Site, São Paulo

080020

Novartis Investigative Site, Barranquilla

128 50

Novartis Investigative Site, Prague

01010

Novartis Investigative Site, Guatemala City

01011

Novartis Investigative Site, Guatemala City

807-8556

Novartis Investigative Site, Kitakyushu

980 8574

Novartis Investigative Site, Sendai

3000 075

Novartis Investigative Site, Coimbra

4099-001

Novartis Investigative Site, Porto

04763

Novartis Investigative Site, Seoul

08036

Novartis Investigative Site, Barcelona